<div id="readability-page-1"><div> <div> , /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde &amp; Associates PC (the &#34;M&amp;A Class Action Firm&#34;), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating <ul type="disc"> <li>Kezar Life Sciences, Inc. (NASDAQ: KZR) related to its sale to Aurinia Pharmaceuticals Inc. Under the terms of the proposed transaction, Kezar shareholders are expected to receive $6.955 per share in cash and one non-transferable contingent value right.</li> </ul> Click here for more information https://monteverdelaw.com/case/kezar-life-sciences-inc/. It is free and there is no cost or obligation to you. <ul type="disc"> <li>Centessa Pharmaceuticals plc (NASDAQ: CNTA) related to its sale to Eli Lilly and Company. Under the terms of the proposed transaction, Centessa shareholders are expected to receive $38.00 per share in cash and one non-transferable contingent value right entitling the holder to receive up to an aggregate of $9.00 subject to the achievement of certain milestones.</li> </ul> Click here for more information https://monteverdelaw.com/case/centessa-pharmaceuticals-plc/. It is free and there is no cost or obligation to you. <ul type="disc"> <li>Affinity Bancshares, Inc. (NASDAQ: AFBI) related to its sale to Fidelity Bancshares (N.C.), Inc. Under the terms of the proposed transaction, Affinity shareholders are expected to receive $23.00 per share in cash.</li> </ul> Click here for more information https://monteverdelaw.com/case/affinity-bancshares-inc-2/. It is free and there is no cost or obligation to you. <ul type="disc"> <li>Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) related to its sale to Biogen, Inc. Under the terms of the proposed transaction, Apellis shareholders are expected to receive $41.00 per share in cash and a non-transferable contingent value right for the right to receive two payments of $2.00 per share each, contingent on certain annual global net sales thresholds being met for SYFOVRE.</li> </ul> Click here for more info https://monteverdelaw.com/case/apellis-pharmaceuticals-inc/. It is free and there is no cost or obligation to you. NOT ALL LAW FIRMS ARE THE SAME. Before you hire a law firm, you should talk to a lawyer and ask: <ol type="1"> <li>Do you file class actions and go to Court?</li> <li>When was the last time you recovered money for shareholders?</li> <li>What cases did you recover money in and how much?</li> </ol> About Monteverde &amp; Associates PC Our firm litigates and has recovered money for shareholders…and we do it from our offices in the Empire State Building. We are a national class action securities firm with a successful track record in trial and appellate courts, including the U.S. Supreme Court. No company, director or officer is above the law. If you own common stock in the above listed company and have concerns or wish to obtain additional information free of charge, please visit our website or contact Juan Monteverde, Esq. either via e-mail at [email protected] or by telephone at (212) 971-1341. Contact: Juan Monteverde, Esq. MONTEVERDE &amp; ASSOCIATES PC The Empire State Building 350 Fifth Ave. Suite 4740 New York, NY 10118 United States of America [email protected] Tel: (212) 971-1341 Attorney Advertising. (C) 2026 Monteverde &amp; Associates PC. The law firm responsible for this advertisement is Monteverde &amp; Associates PC (www.monteverdelaw.com). Prior results do not guarantee a similar outcome with respect to any future matter. SOURCE Monteverde &amp; Associates PC <img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNDA4Jk5ld3NJdGVtSWQ9REMyOTcyMyZUcmFuc21pc3Npb25fSWQ9MjAyNjA0MDgxNDE1UFJfTkVXU19VU1BSX19fX19EQzI5NzIz?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNDA4Jk5ld3NJdGVtSWQ9REMyOTcyMyZUcmFuc21pc3Npb25fSWQ9MjAyNjA0MDgxNDE1UFJfTkVXU19VU1BSX19fX19EQzI5NzIz"/></div> </div></div>

ARKG

CNTA

Class Action Attorney Juan Monteverde is investigating mergers involving Kezar Life Sciences (KZR), Centessa Pharmaceuticals (CNTA), Affinity Bancshares (AFBI), and Apellis Pharmaceuticals (APLS). Shareholders of KZR are expected to receive $6.955 per share, CNTA $38.00 per share, AFBI $23.00 per share, and APLS $41.00 per share, along with contingent value rights in some cases. The firm has a successful track record in recovering funds for shareholders and offers free consultations for those concerned about these transactions.

prnewswire

iShares Biotechnology ETF

Ark Genomic Revolution ETF

Centessa Pharmaceuticals

Direxion S&P Biotech Bull 3X

SPDR S&P Biotech

Invesco Biotechnology & Genome ETF

Affinity Bancshares

iShares Global Healthcare

Apellis Pharma

Proshares Ultra Nasdaq Biotech

First Trust NYSE Arca Biotech Index Fd

VG Health

ALPS Medical Breakthrough

Health Care Select Sector SPDR

Kezar Life Sciences

VanEck Biotech ETF

Invesco Nasdaq Biotechnology ETF

14:15 ETSHAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--KZR, CNTA, AFBI, and APLS